# Epigenetic dysregulated long non-coding RNAs in renal cell carcinoma based on multi-omics data and their influence on target drugs sensibility

## TL;DR

This study identifies epigenetic changes in long non-coding RNAs in kidney cancer, linking them to prognosis and drug response.

## Contribution

The study identifies 12 specific epigenetic dysregulated lncRNAs in renal cancer and their association with prognosis and drug sensitivity.

## Key findings

- 12 specific epigenetic disorders of lncRNA genes were identified in renal cancer.
- 8 lncRNAs serve as prognostic markers for clear cell renal cell carcinoma.
- High-risk scores correlate with better response to axitinib and nilotinib but not sorafenib or sunitinib.

## Abstract

Epigenetic modifications play a crucial role in cancer development, and our study utilized public data to analyze which leads to the discovery of significant epigenetic abnormalities in lncRNAs, offering valuable insights into prognosis and treatment strategies for renal carcinoma.

Public data were obtained from the Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Gene Expression Omnibus (GEO) database. The analysis of the online public data was all completed in R software.

We discovered a great number of epigenetic abnormalities of lncRNA in renal cancer, which is achieved by comparing the following modification and methylation of histone region changes on the promoter and enhancer of lncRNA: H3K27ac, H3K4me1, H3K4me3. As a result, 12 specific epigenetic disorders of lncRNA genes in renal cancer were identified. Finally, based on this lncRNA, we investigated the prognosis of renal cancer samples, among which 8 lncRNA can be seen as markers of prognosis in renal cancer, which had great prediction ability for ccRCC prognosis. Meanwhile, high risk score may pose response better to axitinib and nilotinib, but not sorafenib or sunitinib. Beyond, we observed an elevated level of risk score in immunotherapy non-responders. Further, biological enrichment and immuno-infiltration analysis was conducted to investigate the fundamental differences between patients categorized as high or low risk.

Our research improves the understanding in the function of epigenetic dysregulated long non-coding RNAs in renal carcinoma.